First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Clinical trial NCT03319628 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03319628
Sponsor: Mersana Therapeutics
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Platinum Resistant Ovarian Cancer Non Small Cell Lung Cancer Metastatic

Start date: 2017-12-12
Primary completion: 2023-05-31
Enrollment: 523

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.